Zobrazeno 1 - 10 of 40 pro vyhledávání: '"John Mao"'
1
Akademický článek
Efficacy and safety of GST-HG171 in adult patients with mild to moderate COVID-19: a randomised, double-blind, placebo-controlled phase 2/3 trialResearch in context
Autor: Hongzhou Lu, George Zhang, John Mao, Xiaochun Chen, Yangqing Zhan, Ling Lin, Tianxiang Zhang, Yanan Tang, Feng Lin, Feiyue Zhu, Yuanlong Lin, Yiming Zeng, Kaiyu Zhang, Wenfang Yuan, Zhenyu Liang, Ruilin Sun, Liya Huo, Peng Hu, Yihua Lin, Xibin Zhuang, Zhaohui Wei, Xia Chen, Wenhao Yan, Xiuping Yan, Lisa Mu, Zhuhua Lin, Xinyu Tu, Hongshan Tan, Fuhu Huang, Zhiqiang Hu, Hongming Li, Guoping Li, Haijun Fu, Zifeng Yang, Xinwen Chen, Fu-Sheng Wang, Nanshan Zhong
Publikováno v: EClinicalMedicine, Vol 71, Iss , Pp 102582- (2024)
Summary: Background: GST-HG171 is a potent, broad-spectrum, orally bioavailable small-molecule 3C like protease inhibitor that has demonstrated greater potency and efficacy compared to Nirmatrelvir in pre-clinical studies. We aimed to evaluate the ef
Externí odkaz: https://doaj.org/article/ee8f6c83fea04bdfa8bcbfb122e1bceb
Zobrazit plný text záznamu
4
First-in-Man Safety, Tolerability, and Pharmacokinetics of a Novel and Highly Selective Inhibitor of Matrix Metalloproteinase-12, FP-025: Results from Two Randomized Studies in Healthy Subjects
Autor: John Mao, Zuzana Diamant, Yisheng Lee, Khalid Abd-Elaziz, Kang Ling Wang, Yuhua Li, David Lau, Christine Voors-Pette, Sandy Pan, Benjamin Chien
Publikováno v: Clinical Drug investigation, 41(1), 65-76. ADIS INT LTD
Background and Objectives: Matrix metalloproteinases (MMPs) are proteases with different biological and pathological activities, and many have been linked to several diseases. Targeting individual MMPs may offer a safer therapeutic potential for seve
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd6903f7a04babd0e3ba401dbc439e36
https://doi.org/10.1007/s40261-020-00981-9
Zobrazit plný text záznamu
5
Safety, Tolerability, and Pharmacokinetics of the Novel Hepatitis B Virus Expression Inhibitor GST-HG131 in Healthy Chinese Subjects: a First-in-Human Single- and Multiple-Dose Escalation Trial
Autor: Xiaojiao Li, Yusi Liu, Hanxin Yao, Meng Wang, Lei Gao, Jinfeng Lou, John Mao, Wenqiang Wu, Yixin Zhou, Yanan Tang, Wenhao Yan, Yanbin Hu, Charles Ding, Shuhui Chen, Junqi Niu, Yanhua Ding
Publikováno v: Antimicrob Agents Chemother
GST-HG131, a novel dihydroquinolizinone (DHQ) compound, has been shown to reduce circulating levels of HBsAg in animals. This first-in-human trial evaluated the safety, tolerability, and pharmacokinetic profile of GST-HG131 in healthy Chinese subject
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::abea040d507c96100f23c8f6577a2ea3
https://doi.org/10.1128/aac.00094-22
Zobrazit plný text záznamu
7
Discovery and preclinical evaluations of GST-HG131, a novel HBV antigen inhibitor for the treatment of chronic hepatitis B infection
Autor: Yanbin, Hu, Fei, Sun, Qiang, Yuan, Jinhua, Du, Lihong, Hu, Zhengxian, Gu, Qiong, Zhou, Xiaoting, Du, Shibo, He, Ya, Sun, Qian, Wang, Lirong, Fan, Lina, Wang, Shaohua, Qin, Shuhui, Chen, Jian, Li, Wenqiang, Wu, John, Mao, Yixin, Zhou, Qiaoyun, Zhou, George, Zhang, Charles Z, Ding
Publikováno v: Bioorganic & Medicinal Chemistry Letters. 75:128977
Chronic hepatitis B (CHB) remains a significant health challenge worldwide. The current treatments for CHB achieve less than 10% cure rates, majority of the patients are on therapy for life. Therefore, cure of CHB is a high unmet medical need. HBV su
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cfa50ef849a5cd4f7c56e83138fb9d4e
https://doi.org/10.1016/j.bmcl.2022.128977
Zobrazit plný text záznamu
8
Safety, Tolerability, and Pharmacokinetics of the Novel Hepatitis B Virus Capsid Assembly Modulator GST-HG141 in Healthy Chinese Subjects: a First-in-Human Single- and Multiple-Dose Escalation Trial
Autor: Lizhi Yang, Wenhao Yan, Jiajia Mai, Wenqiang Wu, Min Wu, Junqi Niu, Dong Zhang, Hong Zhang, Yanan Tang, John Mao, Cuiyun Li, Yanhua Ding
Publikováno v: Antimicrob Agents Chemother
Hepatitis B virus capsid assembly modulators (HBV CAMs) are promising, clinically validated therapeutic agents for the treatment of chronic hepatitis B (CHB). The safety, tolerability, and pharmacokinetic (PK) profiles of GST-HG141, a novel HBV CAM,
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::efeacefe4258d9721f11963357d7c535
https://pubmed.ncbi.nlm.nih.gov/34280012
Zobrazit plný text záznamu
10
A phase 3, open-label, multicenter study of a 6-month pre-mixed depot formulation of leuprolide mesylate in advanced prostate cancer patients
Autor: Vladimir Student, Jitka Patockova, Yisheng Lee, Mark DeGuenther, Shih-Tsung Huang, Ben Chien, Ivan Mincik, Neal D. Shore, John Mao, Mindaugas Jievaltas, Chu-Hsuan Hu, Yuhua Li, Kelle Simpson
Publikováno v: World Journal of Urology
Objectives To determine the safety, efficacy and pharmacokinetic (PK) profile of a pre-mixed depot formulation of leuprolide mesylate subcutaneous injectable suspension (LMIS) 50 mg for up to 1 year of treatment for subjects with advanced prostate ca
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8098dd07938a1c9aec977ca25631af9
https://pubmed.ncbi.nlm.nih.gov/30941562
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje